{"id":"https://openalex.org/W2427961817","doi":null,"title":"The cost-effectiveness of pomalidomide for treating patients with relapsed multiple myeloma refractory to both lenalidomide and bortezomib","display_name":"The cost-effectiveness of pomalidomide for treating patients with relapsed multiple myeloma refractory to both lenalidomide and bortezomib","publication_year":2014,"publication_date":"2014-01-01","ids":{"openalex":"https://openalex.org/W2427961817","mag":"2427961817"},"language":"en","primary_location":{"id":"pmh:oai:www.duo.uio.no:10852/41253","doi":null,"is_oa":true,"landing_page_url":"http://hdl.handle.net/10852/41253","pdf_url":"http://hdl.handle.net/10852/41253","source":{"id":"https://openalex.org/S7407064446","display_name":"NORA - Norwegian Open Research Archives","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"info:eu-repo/semantics/masterThesis"},"volume":null,"type":"dissertation","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"http://hdl.handle.net/10852/41253","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5000399541","display_name":"Vera ten Holder","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Vera ten Holder","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5000399541"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.6338000297546387,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.6338000297546387,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.35740000009536743,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T11221","display_name":"Bone health and treatments","score":0.002099999925121665,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pomalidomide","display_name":"pomalidomide","score":0.9470000267028809},{"id":"https://openalex.org/keywords/relapsed-multiple-myeloma","display_name":"relapsed multiple myeloma","score":0.9919999837875366},{"id":"https://openalex.org/keywords/lenalidomide-refractory-disease","display_name":"lenalidomide-refractory disease","score":0.8529999852180481},{"id":"https://openalex.org/keywords/bortezomib-refractory-disease","display_name":"bortezomib-refractory disease","score":0.9990000128746033},{"id":"https://openalex.org/keywords/cost-effectiveness","display_name":"cost-effectiveness","score":0.9440000057220459},{"id":"https://openalex.org/keywords/quality-adjusted-life-years","display_name":"quality-adjusted life years","score":0.7129999995231628},{"id":"https://openalex.org/keywords/dexamethasone","display_name":"dexamethasone","score":0.7599999904632568},{"id":"https://openalex.org/keywords/markov-model","display_name":"Markov model","score":0.8510000109672546},{"id":"https://openalex.org/keywords/weibull-model","display_name":"Weibull model","score":0.718999981880188},{"id":"https://openalex.org/keywords/treatment-costs","display_name":"treatment costs","score":0.5149999856948853},{"id":"https://openalex.org/keywords/health-care-resource-allocation","display_name":"healthcare resource allocation","score":0.5389999747276306},{"id":"https://openalex.org/keywords/national-health-service","display_name":"National Health Service","score":0.6000000238418579}],"concepts":[{"id":"https://openalex.org/C2778524551","wikidata":"https://www.wikidata.org/wiki/Q7227206","display_name":"Pomalidomide","level":4,"score":0.9742459058761597},{"id":"https://openalex.org/C2776063141","wikidata":"https://www.wikidata.org/wiki/Q425681","display_name":"Lenalidomide","level":3,"score":0.9435102939605713},{"id":"https://openalex.org/C2777478702","wikidata":"https://www.wikidata.org/wiki/Q419319","display_name":"Bortezomib","level":3,"score":0.8451396226882935},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.7669198513031006},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.5742390155792236},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5348225235939026},{"id":"https://openalex.org/C2779609412","wikidata":"https://www.wikidata.org/wiki/Q203174","display_name":"Thalidomide","level":3,"score":0.5098966360092163},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.48317232728004456},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.39180788397789},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0580824613571167},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0}],"mesh":[],"locations_count":2,"locations":[{"id":"pmh:oai:www.duo.uio.no:10852/41253","doi":null,"is_oa":true,"landing_page_url":"http://hdl.handle.net/10852/41253","pdf_url":"http://hdl.handle.net/10852/41253","source":{"id":"https://openalex.org/S7407064446","display_name":"NORA - Norwegian Open Research Archives","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"info:eu-repo/semantics/masterThesis"},{"id":"mag:2427961817","doi":null,"is_oa":false,"landing_page_url":"https://www.duo.uio.no/handle/10852/41253","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null}],"best_oa_location":{"id":"pmh:oai:www.duo.uio.no:10852/41253","doi":null,"is_oa":true,"landing_page_url":"http://hdl.handle.net/10852/41253","pdf_url":"http://hdl.handle.net/10852/41253","source":{"id":"https://openalex.org/S7407064446","display_name":"NORA - Norwegian Open Research Archives","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"info:eu-repo/semantics/masterThesis"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9537000060081482,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2427961817.pdf","grobid_xml":"https://content.openalex.org/works/W2427961817.grobid-xml"},"referenced_works_count":48,"referenced_works":["https://openalex.org/W85469694","https://openalex.org/W1536921365","https://openalex.org/W1593173821","https://openalex.org/W1595046345","https://openalex.org/W1784508447","https://openalex.org/W1971305591","https://openalex.org/W1972090779","https://openalex.org/W1973888964","https://openalex.org/W1978393082","https://openalex.org/W1979322286","https://openalex.org/W1982967337","https://openalex.org/W1989778394","https://openalex.org/W1992538067","https://openalex.org/W1993215466","https://openalex.org/W1999899514","https://openalex.org/W2013329800","https://openalex.org/W2020368872","https://openalex.org/W2021954218","https://openalex.org/W2023636833","https://openalex.org/W2031157863","https://openalex.org/W2032077257","https://openalex.org/W2040055959","https://openalex.org/W2044415411","https://openalex.org/W2044436186","https://openalex.org/W2056271161","https://openalex.org/W2062638219","https://openalex.org/W2066800926","https://openalex.org/W2095255742","https://openalex.org/W2097606429","https://openalex.org/W2104879150","https://openalex.org/W2114538178","https://openalex.org/W2120474651","https://openalex.org/W2123159083","https://openalex.org/W2124560610","https://openalex.org/W2125861708","https://openalex.org/W2129087050","https://openalex.org/W2131553265","https://openalex.org/W2135955090","https://openalex.org/W2136541422","https://openalex.org/W2140579395","https://openalex.org/W2146185798","https://openalex.org/W2159953548","https://openalex.org/W2167498902","https://openalex.org/W2170515647","https://openalex.org/W2339528451","https://openalex.org/W2557174020","https://openalex.org/W2894055493","https://openalex.org/W2974794851"],"related_works":["https://openalex.org/W2903792162","https://openalex.org/W4361301662","https://openalex.org/W2790994467","https://openalex.org/W4255512437","https://openalex.org/W2805296407","https://openalex.org/W2759041666","https://openalex.org/W2179584783","https://openalex.org/W3203399710","https://openalex.org/W2766008835","https://openalex.org/W2621926664"],"abstract_inverted_index":{"Background":[0],"Multiple":[1],"myeloma":[2,649],"(MM)":[3],"is":[4,19,39,69,75,97,109,125,246,312,325,344,606,660,666],"a":[5,40,43,165,239,266,284,369,451,456,469,473,533,608,624,671],"neoplastic":[6],"disease":[7],"of":[8,24,85,107,137,148,171,205,287,317,352,359,376,391,405,416,433,478,499,515,550,555,565,568,571,611,633,678],"plasma":[9],"and":[10,27,52,58,152,173,177,226,261,283,298,413,604,654],"the":[11,22,86,92,105,113,119,135,155,180,193,197,203,214,233,249,253,276,293,302,341,355,357,374,392,403,409,419,431,434,461,479,486,496,505,517,546,551,556,563,566,572,620,627,657,676],"second":[12],"most":[13,117],"common":[14,81],"hematological":[15],"cancer.":[16],"The":[17,146,236,244,289,307,315,411,553,631],"malignancy":[18],"incurable,":[20],"but":[21,61],"introduction":[23],"both":[25,652],"lenalidomide":[26,51,151,172,208,653],"bortezomib":[28,153,174,655],"has":[29,55,238],"improved":[30],"survival":[31,166,169,198,220,464],"outcomes":[32,547],"for":[33,42,45,78,83,154,179,216,373,501,512,614,644,675],"patients":[34,46,319,333,645],"with":[35,320,334,646,670],"MM.":[36],"Now":[37],"there":[38,605],"need":[41],"treatment":[44],"who":[47],"become":[48],"refractory":[49,650],"to":[50,71,133,143,191,211,270,401,429,442,449,494,531,574,640,651],"bortezomib.":[53],"Pomalidomide":[54,665],"shown":[56],"efficacy":[57],"acceptable":[59],"safety,":[60],"since":[62],"health":[63,251],"care":[64],"resource":[65],"are":[66,394,559],"scarce,":[67,110],"it":[68],"important":[70],"know":[72],"if":[73],"pomalidomide":[74,108,124,138,158,222,321,360,381,417,500,596,634],"good":[76],"value":[77,372,674],"money":[79],"using":[80],"benchmarks":[82],"cost-effectiveness":[84,136,632],"National":[87],"Health":[88],"Service":[89],"(NHS)":[90],"in":[91,189,213,275,310,354,548,592,626,656],"United":[93],"Kingdom":[94],"(UK),":[95],"which":[96],"\u00a330,000":[98,377,679],"per":[99,346,365,378,662,680],"QALY":[100,366,379,663,681],"gained.":[101,348,664,682],"Because":[102,595],"information":[103,111,149,204,538],"about":[104,112,539],"effectiveness":[106],"patient":[114,162,254,267,527,541,612],"population":[115,120],"that":[116,121,201,511,543],"resembles":[118],"will":[122],"receive":[123],"determined.":[126],"Methods":[127],"A":[128,422,489],"Markov":[129,290],"model":[130,156,215,237,245,291,393,573],"was":[131,159,230,399,427,466,492,509,524],"built":[132],"assess":[134,430],"plus":[139,223,322,635],"low-dose":[140,224,323],"dexamethasone":[141,225,229,324,336,638,643],"compared":[142,639],"high-dose":[144,228,335],"dexamethasone.":[145],"usefulness":[147],"on":[150,157,207,219,248,408,562],"tested":[160],"by":[161,468],"similarity":[163],"through":[164,185],"analysis.":[167],"Kaplan-Meier":[168],"curves":[170],"were":[175,183,439,447],"reconstructed":[176],"parameters":[178,407,415,438,446,455,465],"Weibull":[181],"equation":[182],"estimated":[184],"maximum":[186],"likelihood":[187],"estimation":[188],"order":[190],"reconstruct":[192],"survival.":[194],"Results":[195,306,477],"from":[196,221,227,232,485],"analysis":[199,398,425,491],"show":[200,402],"only":[202,607],"trials":[206],"seem":[209],"reliable":[210],"use":[212],"pomalidomide.":[217],"Data":[218],"obtained":[231,467],"MM-003":[234],"trial.":[235],"10":[240],"years":[241],"time":[242,304],"horizon.":[243,305],"based":[247,561],"different":[250],"states":[252,280],"can":[255,268,597],"experience:":[256],"progression-free":[257],"state,":[258,260],"progressed":[259],"death.":[262],"In":[263],"each":[264],"cycle,":[265],"transfer":[269],"another":[271,590],"stay":[272],"or":[273,588],"remains":[274],"same":[277],"state.":[278],"All":[279,437],"include":[281],"costs":[282,316,498],"determined":[285],"quality":[286,351],"life.":[288],"calculates":[292],"total":[294],"costs,":[295],"life":[296,353],"years,":[297],"QALYs":[299],"gained":[300],"over":[301],"full":[303],"incremental":[308],"gain":[309],"life-years":[311],"0.38":[313],"years.":[314],"treating":[318,332],"almost":[326,482],"6":[327],"times":[328],"as":[329,600],"high":[330,641],"than":[331,619],"(\u00a399,134":[337],"versus":[338],"\u00a317,420).":[339],"Therefore,":[340],"undiscounted":[342],"ICER":[343,358,375,503,518,587,621,677],"\u00a3105,787":[345],"life-year":[347],"By":[349],"including":[350],"model,":[356,536],"becomes":[361],"more":[362],"unattractive":[363],"(\u00a3216,373":[364],"gained).":[367],"With":[368],"standard":[370,672],"threshold":[371,490,586,673],"gained,":[380],"would":[382,519],"not":[383,667],"be":[384,520,578,598],"considered":[385,599,668],"cost-effective.":[386],"Uncertainty":[387,459],"Most":[388],"data":[389,529],"inputs":[390],"uncertain.":[395],"One-way":[396],"sensitivity":[397,424,557],"performed":[400,428,493],"impact":[404],"single":[406],"ICER.":[410,552],"cost":[412],"utility":[414,454],"showed":[418,481],"greatest":[420],"impact.":[421],"probabilistic":[423],"(PSA)":[426],"robustness":[432],"deterministic":[435,487],"model.":[436,488],"altered":[440],"according":[441],"their":[443,593],"distribution.":[444,458,476],"Cost":[445],"assumed":[448],"have":[450,584],"gamma":[452],"distribution,":[453],"beta":[457],"surrounding":[460],"highly":[462],"correlated":[463],"Cholesky":[470],"decomposition":[471],"assuming":[472],"bivariate":[474],"Normal":[475],"PSA":[480],"no":[483,513,525,585],"variation":[484],"seek":[495],"appropriate":[497],"an":[502,601],"under":[504],"NHS":[506,658],"threshold.":[507],"It":[508],"found":[510],"price":[514],"pomalidomide,":[516,616],"acceptable.":[521],"Discussion":[522],"There":[523],"individual":[526,540],"level":[528],"available":[530],"build":[532],"micro":[534],"simulation":[535],"nor":[537],"characteristics":[542],"may":[544,577,583],"influence":[545],"terms":[549],"results":[554],"analyses":[558],"largely":[560],"choice":[564],"distributions":[567],"parameters.":[569],"Transferability":[570],"other":[575,581,617],"settings":[576],"difficult,":[579],"because":[580],"countries":[582],"take":[589],"perspective":[591],"analyses.":[594],"end-of-life":[602],"drug":[603],"small":[609],"amount":[610],"eligible":[613],"receiving":[615],"considerations":[618],"could":[622],"play":[623],"role":[625],"decision-making":[628],"process.":[629],"Conclusion":[630],"low":[636],"dose":[637,642],"relapsed":[647],"multiple":[648],"setting":[659],"\u00a3216,373":[661],"cost-effective":[669]},"counts_by_year":[],"updated_date":"2026-11-08T12:12:28.789561","created_date":"2016-06-24T00:00:00"}